OncoMatch/Clinical Trials/NCT05603884
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Is NCT05603884 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen for leukemia, myeloid, acute.
Treatment: Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen — The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Excluded: BCR ABL1 translocation
chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: hypomethylating agent
Participants have received the following treatments: hypomethylating agents
Cannot have received: (venetoclax)
Participants have received the following treatments: veneclax
Cannot have received: chemotherapy
Participants have received the following treatments: chemotherapy for myelodysplastic syndrome (MDS)
Cannot have received: solid organ transplantation
Participants have received the following treatments: solid organ transplantation
Lab requirements
Kidney function
estimated creatinine clearance ≥ 30 ml/min
Liver function
ast and alt ≤ 3.0 x uln (unless leukemic organ involvement). bilirubin ≤ 1.5 x uln (unless considered due to leukemic organ involvement)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05603884 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with BCR alterations eligible?
No. BCR ABL1 translocation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages